Evidence map›Paper›PMID 41472741›Full record

ArticleFrontiers in immunology2025

CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma.

Marta Rodríguez, Francisco Rojas-Vega, Jesus Frutos Díaz-Alejo, Ignacio Mahillo-Fernández, Cristina Serrano, Alberto López, Teresa Morales-Ruiz, Teresa Roldan-Arjona, Joaquín Sánchez-García, Ana Río-Machín and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marta RodríguezPathology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Francisco Rojas-VegaDepartment of Genetics, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofía University Hospital, Córdoba, Spain.
Jesus Frutos Díaz-AlejoPathology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Ignacio Mahillo-FernándezBioestatistics and Epidemiology Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Cristina SerranoImmunology department, Fundación Jiménez Díaz University Hospital, UAM, Madrid, Spain.
Alberto LópezHematology Department, Fundación Jiménez Díaz University Hospital, Universidad Autónoma of Madrid (UAM), Madrid, Spain.
Teresa Morales-RuizDepartment of Genetics, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofía University Hospital, Córdoba, Spain.
Teresa Roldan-ArjonaDepartment of Genetics, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofía University Hospital, Córdoba, Spain.
Joaquín Sánchez-GarcíaHematology Department, Reina Sofía University Hospital/Maimonides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba, Córdoba, Spain.
Ana Río-MachínExperimental Hematology Lab, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, UAM, Madrid, Spain.
Daniel MorilloHematology Department, Fundación Jiménez Díaz University Hospital, Universidad Autónoma of Madrid (UAM), Madrid, Spain.
M Angeles PérezHematology Department, Fundación Jiménez Díaz University Hospital, Universidad Autónoma of Madrid (UAM), Madrid, Spain.
Raúl CórdobaHematology Department, Fundación Jiménez Díaz University Hospital, Universidad Autónoma of Madrid (UAM), Madrid, Spain.
Pilar Llamas-SilleroHematology Department, Fundación Jiménez Díaz University Hospital, Universidad Autónoma of Madrid (UAM), Madrid, Spain.
Socorro María Rodríguez-PinillaPathology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Juana Serrano-LópezExperimental Hematology Lab, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, UAM, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) has worse outcomes than the germinal center B-cell (GCB) subtype, but underlying molecular mechanisms remain poorly understood. Methods: Transcriptomic analysis on 43 DLBCL samples (23 GCB and 20 ABC) was performed using NanoString PanCancer Immune Profiling Panel with 30 cell-of-origin genes. Tumor microenvironment characterization was performed using CIBERSORTx and gene set enrichment analysis (GSEA) deconvolution. Based on our previous findings of MAPK10 downregulation in ABC lymphomas, MAPK10 promoter methylation was studied via pyrosequencing. Prognostic biomarkers were identified using the Cox regression and least absolute shrinkage and selection operator (LASSO) regularization. Therapeutic candidates were identified through connectivity mapping. Results: ABC lymphomas showed distinct profiles with the overexpression of Conclusions: We validated

Indexed as

Biomarkers, TumorLymphoma, Large B-Cell, DiffuseAdultAgedDNA MethylationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorCCL18DLBCLLASSOMAPK10RNA-seqTME

Identifiers

PMID41472741
PMCPMC12745396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.